

Lecture 5

Monday, October 2, 2023 10:01



BIOS522_Slides5



BIOS 522: Survival Analysis Methods

Lecture 5:

Introduction to the Cox model

Previously

- Estimated the survival function using the Kaplan-Meier estimator
- Compared survival functions using the log-rank test
- Adjusted for categorical covariates using the stratified log-rank test
- Defined the hazard function and its relationship to the survival function

2

ORIGINAL ARTICLE

Trastuzumab plus Adjuvant Chemotherapy for Operable HER2-Positive Breast Cancer

The primary predictor of interest is trial arm (with or without trastuzumab). Researchers also considered the study (trial B-31 vs. trial N9831), intended chemotherapy schedule (every three weeks vs. weekly), nodal status (0, 1-3, 4-9, or 10+ positive nodes), and hormone-receptor status (estrogen- or progesterone-receptor positive vs. estrogen- and progesterone-receptor negative).

Comparison of the two groups was based on a log-rank test, stratified according to the study trial, intended chemotherapy schedule, nodal status, and hormone-receptor status. Thus, there were $2 \times 2 \times 4 \times 2 = 32$ strata

The stratified log-rank test p-value is <0.0001 , indicating **significant improvement in disease-free survival** in the trastuzumab group adjusting for key covariates.




Figure 2. Kaplan-Meier Estimates of Disease-free Survival

3

Stratified log-rank test

But this regional separately 32x!

- The stratified log-rank test stratified over **32 (!)** unique strata
 - Women in trial B-31 on weekly chemo with 0-3 positive lymph nodes with hormone receptor negative cancer
 - Women in trial B-31 on weekly chemo with 4-9 positive lymph nodes with hormone receptor positive cancer (and so on...)
- We compare patients with and without trastuzumab in each strata
- In this way, the stratified log-rank test adjusts for the stratifying variables

But ...

4

Limitations of the stratified log-rank test

- It **does not allow us to measure the simultaneous impact** of these variables on survival
- It **does not borrow information** across similar groupings
 - Same trial, hormone receptor status, chemo frequency, but different # of nodes
- We can **only stratify on categorical** covariates
 - We may wish to model the number of positive lymph nodes as a continuous variable
- It **does not provide a summary** statistic for the effect size \rightarrow can do p-value but doesn't provide estimate of effect
- Thus, we may prefer a regression framework...

5

Regression models

Dependent variable = function of independent variables

Linear regression: *mean of continuous var*

$$E[Y_i] = \beta_0 + \beta_1 X_{i1} + \dots + \beta_k X_{ik}$$

Intercept that characterizes the dependent variable in the reference group

Logistic regression: *log odds*

$$\log \left[\frac{p_i}{1 - p_i} \right] = \beta_0 + \beta_1 X_{i1} + \dots + \beta_k X_{ik}$$

Coefficients that characterize the effect on the dependent variable of a one-unit change in the independent variable

6

Cox proportional hazards regression

Dependent variable = function of independent variables

Cox model:

$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$$

Baseline hazard function that characterizes the dependent variable in the reference group

this is a FUNCTION of t, no longer just mean or log odds

*hazard in group w/ all covariates = 0
Assuming a common shape, which is shared across groups*

covariates are multiplied (multiplicative effect)

Coefficients that characterize the effect on the dependent variable of a one-unit change in the independent variable

7

Coefficients of the Cox model

- β_j is the **log hazard ratio** for the j th covariate
- $\exp(\beta_j)$ is the **hazard ratio** for the j th covariate

- For a **binary covariate**, this is the hazard ratio comparing the group with $X_{ij} = 1$ vs. the group with $X_{ij} = 0$
 - (holding all other covariates constant)
- For a **continuous covariate**, this is the hazard ratio for a one-unit increase in X_{ij} , e.g. $X_{ij} = 10$ vs. $X_{ij} = 9$
 - (holding all other covariates constant)

8

Ratio of hazards

holding other covariates constant

$$\begin{aligned}\frac{h'_i(t)}{h_i(t)} &= \frac{h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_j (X_{ij} + 1) + \dots + \beta_k X_{ik})}{h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_j X_{ij} + \dots + \beta_k X_{ik})} \\ &= \exp[(\beta_1 X_{i1} + \dots + \beta_j (X_{ij} + 1) + \dots + \beta_k X_{ik}) - (\beta_1 X_{i1} + \dots + \beta_j X_{ij} + \dots + \beta_k X_{ik})] \\ &= \exp[\beta_j (X_{ij} + 1) - \beta_j X_{ij}] \\ &= \exp(\beta_j)\end{aligned}$$


$$\log \left[\frac{h'_i(t)}{h_i(t)} \right] = \beta_j$$

log hazard ratio

Hazard ratio for one unit change in a covariate holding others zero

9

Example: Breast cancer recurrence



• Stage III vs. Stage I [ref]

- Hazard ratio $\approx 2 \rightarrow$ Stage III is 2x than stage I
- Coefficient ≈ 0.69

\hookrightarrow about the log of 2
if this is the only covariate

• Stage I vs. Stage III [ref]

- Hazard ratio $\approx 0.5 \rightarrow$ stage I is 0.5x than stage III
- Coefficient ≈ -0.69

reciprocal

Source: Cheng et al. (2012) Cancer, Epi, Biomarkers & Prevention [10.1158/1055-9965.EPI-11-1089](https://doi.org/10.1158/1055-9965.EPI-11-1089)

10

Example: Lung cancer mortality

- Goal: Study risk factors associated with 3-year overall survival after lung cancer surgery
- Population: 601 lung cancer patients who underwent surgical treatment
- Outcome variable: Time from surgery to death by any cause
- Predictor variables: Age, gender, forced expiratory volume (FEV1), cancer stage, neoadjuvant therapy, and decortication

Source: Brembilla et al. (2018) J Thorac Dis [10.21037/jtd.2018.06.15](https://doi.org/10.21037/jtd.2018.06.15)

11

Example: Lung cancer mortality

Covariates	Coefficient	Standard error	P value	HR	95% CI	
					Lower	Upper
Age (0: ≤70, 1: >70)	0.584	0.191	0.002	1.793	1.232	2.610
Gender (0: M, 1: F)	0.276	0.230	0.229	1.318	0.840	2.068
FEV1 (0: <80, 1: ≥80)	-0.197	0.165	0.233	0.821	0.594	1.135
Simplified cancer stage						
Stage 2	1.509	0.528	0.004	4.523	1.609	12.720
Stage 3	1.616	0.511	0.002	5.031	1.848	13.700
Stage 4	1.808	0.619	0.004	6.097	1.811	20.528
Neoadjuvant therapy (0: no, 1: yes)	0.055	0.188	0.769	1.057	0.731	1.529
Decortication (0: no, 1: yes)	0.471	0.232	0.043	1.602	1.016	2.527

FEV1, forced expiratory volume in 1 second.

Source: Brembilla et al. (2018) | Thorac Dis [10.21037/jtd.2018.06.15](https://doi.org/10.21037/jtd.2018.06.15)

12

(Proportional hazards)

PH with multiple covariates

Reference group: Unexposed, Young adults

- Say we have two covariates
 - $X_{i1} = 1$ if exposed, 0 if unexposed
 - $X_{i2} = 1$ if older, 0 if younger

- Fit a Cox model


$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \beta_2 X_{i2})$$

$$h_i(t) = h_0(t) \text{ for unexposed younger adults}$$

$$h_i(t) = h_0(t)e^{\beta_1} \text{ for exposed younger adults}$$

$$h_i(t) = h_0(t)e^{\beta_2} \text{ for unexposed older adults}$$

$$h_i(t) = h_0(t)e^{\beta_1 + \beta_2} \text{ for exposed older adults}$$



13

PH with multiple covariates

- Say we have two covariates
 - $X_{i1} = 1$ if exposed, 0 if unexposed
 - $X_{i2} = 1$ if older, 0 if younger

- Fit a Cox model

$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \beta_2 X_{i2})$$

$$h_i(t) = h_0(t) \text{ for unexposed younger adults}$$

$$h_i(t) = h_0(t)e^{\beta_1} \text{ for exposed younger adults}$$

$$h_i(t) = h_0(t)e^{\beta_2} \text{ for unexposed older adults}$$

$$h_i(t) = h_0(t)e^{\beta_1 + \beta_2} \text{ for exposed older adults}$$

- Equivalently

$$\rightarrow \log(h_i(t)) = \log(h_0(t)) + \beta_1 X_{i1} + \beta_2 X_{i2}$$

so the log hazard will just be increased (shifted up) by the β 's

$$\rightarrow \log(h_i(t)) = \log(h_0(t))$$


$$\rightarrow \log(h_i(t)) = \log(h_0(t)) + \beta_1$$

$$\rightarrow \log(h_i(t)) = \log(h_0(t)) + \beta_2$$

$$\rightarrow \log(h_i(t)) = \log(h_0(t)) + \beta_1 + \beta_2$$

14

PH on the log scale




Suggests that one way to examine the proportional hazards assumption is to check that the log hazard functions are parallel

15

PH on the log cumulative hazard scale

$$H_1(t) = \exp(\beta)H_0(t)$$

$$\log(H_1(t)) = \beta + \log(H_0(t))$$



Source: Wang and Li (2017) Quant Biosci <https://doi.org/10.22283/qbs.2017.36.2.85>

Suggests that another way to check the proportional hazards assumption is by seeing if the log cumulative hazard functions are parallel


16

PH on the survival scale

$$S_1(t) = [S_0(t)]^{\exp(\beta)}$$

- Under the proportional hazards assumption, the survival curves diverge over time (until survival approaches 0)


because there is a steady divergence
 ↳ you run out of people



Source: <http://www.sthda.com/english/wiki/cox-proportional-hazards-model>

17

When proportional hazards is violated



Relation between two groups
is not the same
over time → can't fit one value
if the relationship changes
over time

Source: <http://onbiostatistics.blogspot.com/2020/10/visual-inspection-and-statistical-tests.html>


18

Understanding the Cox model

Assuming this basic format:

$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$$

- Instead of an intercept, the baseline hazard is an entire FUNCTION
- This function can take any of an infinite number of shapes



19

Semiparametrics

$$h_i(t) = h_0(t) \exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$$

- The baseline hazard function $h_0(t)$ is **nonparametric** → no assumption about distr. of fun
- The hazard ratio $\exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})$ is **parametric** → we ARE assuming for hazard ratio
 - We assume that the effect of each covariate is to multiply the hazard
 - We assume that the hazards are proportional (constant ratio for all t)
- The Cox model is **semiparametric**

20

Inference on the Cox model

- We are most interested in estimating the terms β_1, \dots, β_k
- Fitting the nonparametric baseline hazard is more complex
 - We might consider $h_0(\cdot)$ to be a “nuisance”

- It is possible to estimate β_1, \dots, β_k without estimating $h_0(\cdot)$

$$L(\beta_1, \dots, \beta_k) L(h_0(\cdot), \beta_1, \dots, \beta_k)$$

only coefficients hazard fun
likelihood breaks into 2 terms

*or making
distasteful
assumption*

- The left-hand term is known as the **Cox partial likelihood**
- We can find the values $\hat{\beta}_1, \dots, \hat{\beta}_k$ that maximize the partial likelihood
 - These are known as *maximum partial likelihood estimators*

21

Cox partial likelihood \rightarrow aka $L(\beta_1, \dots, \beta_k)$ from previous slide

- Consider unique failure times T_1, \dots, T_m
- At time T_i , individual i fails; the risk set at that time is $R(T_i)$
- The partial likelihood is the product over all m unique failure times:

$$\prod_{i=1}^m \frac{\exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})}{\sum_{j \in R(T_i)} \exp(\beta_1 X_{j1} + \dots + \beta_k X_{jk})}$$

hazard rate for person who DID fail
VS.
hazard of everyone still at risk

- The contribution at each failure time is **the conditional probability that individual i was the one to fail out of risk set $R(T_i)$**

22

Notes on the partial likelihood

you can rescale, etc.

$$\prod_{i=1}^m \frac{\exp(\beta_1 X_{i1} + \dots + \beta_k X_{ik})}{\sum_{j \in R(T_i)} \exp(\beta_1 X_{j1} + \dots + \beta_k X_{jk})}$$

- Note that the partial likelihood does not contain $h_0(t)$
- Note that this calculation **assumes all failure times are unique;** modifications are required to accommodate tied times

need to be able to assign who failed

23

Methods for handling ties

Method	Approach	Advantages/Disadvantages
Exact method	Considers all $d_i!$ possible combinations of breaking ties	(++) Most accurate (-) Computationally complex
Efron approximation	Approximates the mean denominator of the Exact method	(+) Accurate (+) Computationally efficient
Breslow approximation	Ignores the fact that failures are removed from the risk set	(+) Simplest (-) Least accurate

24

Prediction

- Given a final model, we are usually most interested in reporting which covariates increase/decrease survival
 - Hazard ratios = $\exp(\hat{\beta})$
 - Hypothesis tests
- Less frequently, we also wish to generate predictions of survival based on our semiparametric regression model
 - Survival curve, median survival, survival at a landmark time
 - Calculated for a particular set of covariates

25

Prediction

- The proportional hazards model gives us a framework for making predictions

hazard function $\hat{h}_i(t) = \hat{h}_0(t) \exp(\hat{\beta}_1 X_{i1} + \dots + \hat{\beta}_k X_{ik})$

cumulative hazard function $\hat{H}_i(t) = \hat{H}_0(t) \exp(\hat{\beta}_1 X_{i1} + \dots + \hat{\beta}_k X_{ik})$

Survival $\hat{S}_i(t) = \exp(-\hat{H}_i(t))$

- Using partial likelihood estimation, we estimate $\hat{\beta}_1, \dots, \hat{\beta}_k$ but not the flexible baseline hazard or cumulative hazard functions

26

Baseline cumulative hazard

- **Breslow estimator** of the baseline cumulative hazard function:

$$\tilde{H}_0(t) = \sum_{j:t_j \leq t} \frac{d_j}{\sum_{i=1}^{n_j} \exp(\hat{\beta}_1 X_{i1} + \dots + \hat{\beta}_k X_{ik})}$$

- Related to the Nelson-Aalen cumulative hazard estimator:

$$\tilde{H}(t) = \sum_{j:t_j \leq t} \frac{d_j}{n_j}$$

instead, sum each individual's hazard ratio

27

Prediction

- We can predict survival at time t for a person with covariates X_{i1}, \dots, X_{ik} as:

$$\begin{aligned} \tilde{S}_i(t) &= \exp(-\tilde{H}_0(t) \exp(\hat{\beta}_1 X_{i1} + \dots + \hat{\beta}_k X_{ik})) \\ &= [\tilde{S}_0(t)]^{\exp(\hat{\beta}_1 X_{i1} + \dots + \hat{\beta}_k X_{ik})} \\ &= [e^{-\tilde{H}_0(t)}]^{\exp(\hat{\beta}_1 X_{i1} + \dots + \hat{\beta}_k X_{ik})} \end{aligned}$$

28

Example: Liver disease



Journal of Hepatology 40 (2004) 937-943

Journal of
Hepatology
www.elsevier.com/locate/jhep

Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease

Adnan Said¹, John Williams¹, Jeremy Holden¹, Patrick Remington², Ronald Gangnon³, Alexandru Musat¹, Michael R. Lucey^{1,5}

- Goal: An existing **prognostic model** for **end stage liver disease** (MELD) has been validated for short-term and intermediate-term mortality outcomes for patients with cirrhosis and end-stage liver disease. This model is valuable for transplant planning. Researchers sought to **extend this model** for predicting outcomes for patients with early-stage cirrhosis and alcoholic hepatitis.

Good for transplant stuff seeing who will respond best

29

Example: Liver disease



Journal of Hepatology 40 (2004) 977-983

Journal of
Hepatology
www.elsevier.com/locate/jhep

Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease

Adnan Said¹, John Williams¹, Jeremy Holden¹, Patrick Remington², Ronald Gangnon³, Alexandru Musat¹, Michael R. Lucey^{1,5}

- **Population:** They constructed a retrospective cohort using data on **1611 patients with chronic liver disease** from the hepatology clinics and inpatient service of a university hospital between January 1994 and December 2001.
- **Outcome variable:** Survival was calculated from the **date of first clinical contact to date of death**, abstracted from hospital records and the national social security death index. Survival was censored if the patient received a liver transplant.

30

Example: Liver disease



Journal of Hepatology 40 (2004) 977-983

Journal of
Hepatology
www.elsevier.com/locate/jhep

Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease

Adnan Said¹, John Williams¹, Jeremy Holden¹, Patrick Remington², Ronald Gangnon³, Alexandru Musat¹, Michael R. Lucey^{1,5}

- **Predictor variables:** The primary predictor of interest was **MELD score**, which was calculated based on serum creatinine, bilirubin, and INR (international normalized ratio, measure of liver function) measured at the first visit. The continuous MELD score was then categorized (MELD categories 1-4, scores ≤ 9 , 10-19, 20-29, ≥ 30 , respectively). Higher categories indicate poorer liver function.
- **Other prognostic variables** considered included age, gender, race, etiology of chronic liver disease (alcoholic liver disease, hepatitis C virus, other), diagnosis of end-stage liver disease, and CTP score (another prognostic measure).

31

Example: Liver disease



Journal of Hepatology 40 (2004) 977-983

Journal of
Hepatology
www.elsevier.com/locate/jhep

Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease

Adnan Said¹, John Williams¹, Jeremy Holden¹, Patrick Remington², Ronald Gangnon³, Alexandru Musat¹, Michael R. Lucey^{1,5}

- **Statistical analysis:** Researchers fit a **Cox proportional hazards model** to identify covariates that were predictive of survival in a model that already includes MELD score. **Survival probabilities** for each MELD category were predicted by Kaplan-Meier and by Cox regression (after adjusting for other covariates).

32

Results: Survival curves are plotted in Figure 1 (Kaplan-Meier, left; Cox model, right).




Fig. 1. Survival of cohort with chronic liver disease. Observed survival curves (Kaplan-Meier estimates) and predicted (Cox regression) survival curves predict increasing mortality with higher MELD categories. Categories: 1 = MELD ≤ 9 , 2 = MELD 10 to 19, 3 = MELD 20 to 29, 4 = MELD ≥ 30 . Pairwise comparisons: 1 vs 2, $p < 0.0001$; 1 vs 3, $p < 0.0001$; 1 vs 4, $p < 0.0001$; 2 vs 3, $p = 0.004$; 2 vs 4, $p < 0.0001$; 3 vs 4, $p < 0.0001$. Comparison of observed (A) and predicted (B) curves: Category 1 (≤ 9), $p = 0.95$; Category 2 (10–19), $p = 0.05$; Category 3 (20–29), $p = 0.34$; Category 4 (≥ 30), $p = 0.51$; Overall (non-categorized MELD), $p = 0.18$.

Said et al. (2004)

33

Why is this smoother?
proportional hazards model
the predicted curves are fit using ALL of the data, people just have different weights
and multiplying by proportional terms

Example: Liver disease



Journal of Hepatology 40 (2006) 977–983

Journal of
Hepatology
www.elsevier.com/locate/jhep

Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease

Adnan Said¹, John Williams¹, Jeremy Holden¹, Patrick Remington², Ronald Gangnon³,
Alexandro Musat¹, Michael R. Lucey^{1,5}

- Results, continued: **MELD score is a significant predictor of survival**, capturing large differences in short-term survival between the risk categories.
- There is **good concordance** between observed and predicted survival. Note that the curves generated by the Cox method are smoother, as they borrow information across all participants. They also share the same basic shape, because their hazard functions have the same underlying shape.

34

Looking ahead

Lecture 6

- Interpreting hazard ratios for binary and continuous data
- Hypothesis testing
- Interactions, transformations, polynomials, splines

Lecture 7

- Examining the proportional hazards assumption
- Residuals
- Goodness of fit
- Visual diagnostics
- Model selection

Lecture 8

- Time-dependent covariates
- Time-varying effects
- Stratified Cox model

35